Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Arte...(m those contained in the forward-looking...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
Date:5/20/2009
m those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation
Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2009 PR Newswire. All rights reserved |
Related medicine technology :
1. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
2. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
3. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
4. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
5. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
6. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
7. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
8. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
9. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
10. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
11. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
Post Your Comments:
Breaking Medicine Technology:Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2Statement from IDF on studies suggesting possible link between insulin glargine and cancer 50295 1Vietnamese drug authority teams with United States standards setting organization 50291 1Vietnamese drug authority teams with United States standards setting organization 50291 2ICSI or IVF 3A Babies born from frozen embryos do just as well 9047 1ICSI or IVF 3A Babies born from frozen embryos do just as well 9047 2ICSI or IVF 3A Babies born from frozen embryos do just as well 9047 3
Other Medicine Technology:Complications and Costs for Obesity Surgery Declining 2Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer 2
Breaking Medicine News(10 mins):Health News:Better Vaccine Planning Needed, Committee Finds 2Health News:Better Vaccine Planning Needed, Committee Finds 3Health News:The Visiting Nurse Association of Greater Philadelphia Expands Service to Bucks County 2Health News:Mass Murderers: Why Do They Kill? 2Health News:Controversy Over Reid Fundraiser Exemplifies Need for Fair Elections 2
[0] Stem Cells Turned Into AIDS Killers in Lab Tests[0] Better Vaccine Planning Needed, Committee Finds[0] The Visiting Nurse Association of Greater Philadelphia Expands Service to Bucks County[0] Mass Murderers: Why Do They Kill?[0] Controversy Over Reid Fundraiser Exemplifies Need for Fair Elections
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |